ArticleBMC medical imaging2026
Gray matter atrophy mediated the association between glymphatic function and cognition in Alzheimer's disease: a multicenter DTI-ALPS study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough emerging evidence links glymphatic dysfunction to Alzheimer’s disease (AD), whether this association depends on structural brain changes remains unknown. In this study, we employed Diffusion Tensor Imaging Analysis along the Perivascular Space (DTI-ALPS) to assess the glymphatic alterations along the AD continuum in a Chinese cohort and explored whether these alterations are statistically mediated by gray matter (GM) or white matter (WM) atrophy as anchored by the ALPS-index.
methodsWe assessed glymphatic function using the ALPS-index in 200 participants with normal controls (NC, n = 72), mild cognitive impairment (MCI, n = 52), and AD dementia (n = 76) from three hospitals. Data were harmonized using ComBat to correct batch effects. Group differences in ALPS-index, gray matter volume fraction (GMVF), and white matter volume fraction (WMVF) were analyzed via ANOVA. Correlations among the DTI-ALPS index, GMVF/WMVF, and cognitive/functional outcomes were analyzed. Multivariate ANOVA assessed regional GM/WM differences. Multiple regression identified brain regions anchored to ALPS-index. Mediation analyses tested whether GMVF, WMVF, or GM/WM regions statistically mediated the relationship between ALPS-index and outcomes.
resultsThe ALPS-index demonstrated progressive decline across groups (NC:1.45 ± 0.13; MCI:1.33 ± 0.14; AD:1.22 ± 0.13; F = 19.80, p < 0.001), with medium-to-large effect sizes (d = 0.48–0.82). The ALPS-index was correlated with the mini mental state examinations (MMSE) (β = 0.292, p (FDR) = 0.002), montreal cognitive assessment (MoCA) (β = 0.307, p (FDR) = 0.002) and activity of daily living scale (ADL) (β = -0.210, p (FDR) = 0.020). Both the GMVF and WMVF, as well as the regional alterations in GM and WM, showed statistically significant differences between the AD and NC groups, whereas no significant alterations were observed in the MCI group. GMVF, WMVF, left hippocampus and right parahippocampal gyrus mediated the relationship between the ALPS-index and cognitive function/functional status.
conclusionOur findings demonstrate progressive glymphatic dysfunction across the AD continuum. GMVF and specific GM regions were statistically associated with the relationship between glymphatic function and cognitive function/functional status, indicating an indirect association between glymphatic impairment and AD progression via GM degeneration. These results support glymphatic function associated structural degeneration as potential tools for AD monitoring and highlight GM preservation as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.